

BDMAI BULLETIN



From the Desk of President

Dear Members,

Wish you all a very Happy New Year 2026.

At BDMAI, 2025 has been an eventful and productive year. The Seminar on AI & Digitalization in Bulk Drug Manufacturing received an overwhelming response from our members, clearly reflecting the industry's keen interest in adopting advanced technologies to improve efficiency and competitiveness. This encouraging response motivates us to continue organizing such knowledge-driven and future-oriented initiatives. In this context, we are exploring the possibility of organizing a seminar on Flow Chemistry, an emerging and highly significant area in bulk drug manufacturing, in the near future.

BDMAI also actively participated in the recently held CPhI India and Global Chem Show. These platforms enabled the Association to reach out to bulk drug manufacturers from other States and further strengthen industry connections. I am pleased to share that the BDMAI e-Marketing Portal, a unique initiative aimed at creating a comprehensive digital ecosystem for the bulk drug industry, received excellent appreciation from both manufacturers and traders during these events. This platform enables members to showcase their products, connect with potential customers, and enhance market visibility. Members are encouraged to make effective use of this facility.

Recently, a senior official delegation from the Industries Development Authority of Uttar Pradesh (UPSIDA) visited Hyderabad and interacted with some of our members to promote the Bulk Drug Park being developed in Uttar Pradesh. They have expressed keen interest in showcasing the infrastructure and facilities being developed at the Park to interested members during the Pharma Conclave being organized on 3rd February 2026 at Lucknow, where the Hon'ble Chief Minister of Uttar Pradesh will be the Chief Guest. The detailed program of the event will be shared shortly.

I look forward to your continued support and active participation in BDMAI's upcoming programs.

With Warm regards

Ch. A P Rameswara Rao
National President

In this Bulletin
you can expect

Global Pharma News

New Drug Developments, Investments & JVs, Drug Approvals,

BDMAI Activities

Representations, Circulars, Events

Technical & Commercial Articles

Data of Import & Export of Bulk Drugs

New Drug Developments:

Genfit reports promising phase 1b data in cholangiocarcinoma

Genfit has announced encouraging preliminary results from its phase 1b clinical trial evaluating investigational drug GNS561 in combination with a MEK inhibitor (MEKi) in patients with KRAS mutated cholangiocarcinoma (CCA). The rare and aggressive cancer of the bile ducts is often diagnosed late and has limited treatment options. The study enrolled patients with advanced CCA who had failed one or two prior lines of therapy. Nine patients with measurable disease were included, with four reaching tumour assessment at week six.

Pharma Times 11.12.2025

GRI Bio reports positive phase 2a data in idiopathic pulmonary fibrosis

GRI Bio has announced positive topline results from its phase 2a clinical trial evaluating GRI-0621 in idiopathic pulmonary fibrosis (IPF). The study met its primary and secondary endpoints, showing the drug was well tolerated over 12 weeks and demonstrated signs of disease-modifying activity. The company reported no drug-related severe or serious adverse

events. Common side effects included dry skin, dry lips and muscle or joint pain. Importantly, there were no increases in cough or gastrointestinal disorders compared to placebo. Eighty per cent of subjects were taking background pirfenidone or nintedanib. GRI-0621 also showed improvements in forced vital capacity (FVC). At 12 weeks, 39% of treated subjects experienced an increase in FVC, while 80% of those on placebo saw a decline.

Pharma Times 11.12.2025

Eli Lilly announces Positive Results for Retatrutide

Eli Lilly has announced positive topline results from the Phase III TRIUMPH-4 trial for its investigational triple-agonist, retatrutide. In adults with obesity and knee osteoarthritis, the 12-mg dose delivered an average weight loss of a 28.7% of their body weight at 68 weeks. Crucially, the trial also met its secondary endpoints, showing clinically meaningful reductions in osteoarthritis pain.

Pharma Pulse 11.12.2025

J&J gains label expansion approval for Akeega in mCSPC

Johnson & Johnson (J&J) has secured a US label expansion for its next-generation oncology combination, Akeega, in breast cancer gene 2 (BRCA-2)-mutated, metastatic, castration-sensitive prostate cancer (mCSPC). A combination of niraparib and J&J's androgen inhibitor, abiraterone in a pill format, J&J's therapy plus prednisone received FDA approval in mCSPC based on positive results of the Phase III AMPLITUDE study (NCT04497844), which found that Akeega plus prednisone and androgen deprivation therapy (ADT) cut the risk of disease progression or death by 54% compared with standard of care (SoC). J&J gained the rights to investigate and commercialise nipaib in [prostate cancer](#) from the drug's creator, Tesaro, which was later acquired by GSK in 2018.

Pharmaceutical Technologies 15.12.2025

HUTCHMED begins phase 3 stage of pancreatic cancer trial

HUTCHMED has advanced its ongoing study of surufatinib and camrelizumab for treatment-naïve metastatic pancreatic ductal adenocarcinoma, initiating the phase 3 stage of its phase 2/3 trial in China. The company confirmed that the first patient received a dose on 30 December 2025. Pancreatic ductal adenocarcinoma is the most common and aggressive form of

pancreatic cancer, accounting for more than 90% of cases. Globally, around 511,000 people were diagnosed with pancreatic cancer in 2022 and approximately 467,000 died from the disease. Survival remains poor, with fewer than 10% of patients living five years after diagnosis. In China, 119,000 cases and 106,000 deaths were recorded in 2022. Standard treatments such as chemotherapy, surgery and radiotherapy have delivered limited improvements, and fewer than one in five patients with metastatic disease survive beyond a year.

Pharma Times 5.1.2026

Zenas reports strong phase 3 results for obexelimab in IgG4-related disease

Zenas BioPharma has announced positive findings from its phase 3 INDIGO trial evaluating obexelimab in patients with Immunoglobulin G4-related disease (IgG4-RD), reporting a statistically significant reduction in flare risk and favourable safety outcomes. The company said the study met its primary endpoint, with obexelimab delivering a 56% reduction in the risk of IgG4-RD flare compared with placebo during the 52-week controlled period. All four key secondary endpoints were also achieved, including reductions in investigator-assessed flare, fewer flares requiring rescue therapy, higher rates of complete remission and lower cumulative use of rescue medication. Infection rates were lower in the treatment arm and injection site reactions were similar across groups.

Pharma Times 5.1.2026

Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation. The company said the first participants have now entered the randomised, double-blind, placebo-controlled study, which will recruit 200 patients across eight European countries and is expected to complete in the first quarter of 2027. The trial's primary efficacy endpoint is atrial fibrillation burden, defined as the percentage of time a participant spends in atrial fibrillation. A key safety measure is the occurrence of ventricular proarrhythmia, a major limitation of existing antiarrhythmic drugs. To support continuous assessment, all participants will receive an implantable loop recorder enabling round-the-clock cardiac rhythm monitoring.

Investments & JVs

Novartis and UK-based Relation forge R&D deal worth up to \$1.7bn

Novartis has teamed up with AI-led biotech Relation Therapeutics in a deal worth up to approximately \$1.7bn to discover and develop novel targets for atopic diseases. Through the agreement, the Swiss big pharma company will hand over \$55m in

upfront, equity investment and R&D funding payments for the global development and commercialisation rights to any resulting targets created through this partnership. Alongside this upfront payment, Relation will be eligible to receive up to \$1.7bn in milestone payments, as well as tiered royalties on net sales of any products that make it to market.

Pharmaceutical Technologies 11.1.2025

Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline

Sobi has entered into an agreement to acquire Arthrosi Therapeutics, a private late-stage biotechnology company specialising in the development of a treatment for gout. The acquisition will strengthen Sobi's gout portfolio, bringing with it pozdeutinurad (AR882), an investigational once-daily oral urate transporter 1 (URAT1) inhibitor. Pozdeutinurad is currently being evaluated in two global phase 3 studies, with results expected in 2026. It is intended for the treatment of progressive and tophaceous gout. Gout is the most common form of inflammatory arthritis. It is caused by high levels of uric acid in the body that, if accumulated around the joints and other tissues, can result in painful flares. Untreated gout can cause chronic joint damage and other serious issues.

Pharma Times 16.12.2025

MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute

MRM Health, a clinical-stage biopharmaceutical company developing microbiome-based therapeutics for inflammatory diseases and immuno-oncology, has announced its collaboration with Professor Emile Voest, senior group leader at the Netherlands Cancer Institute (NKI) and senior investigator at Oncode Institute. MRM hopes to accelerate the development of novel live biotherapeutic products (LBPs) to improve the efficacy of immune checkpoint inhibitors (ICIs) in cancer treatment, assisted by Voest's established expertise in tumour microbiome research and translational oncology.

Pharma Times 18.12.2025

Amgen buys Dark Blue Therapeutics in \$840m oncology deal

Amgen has agreed to acquire UK-based biotech Dark Blue Therapeutics for up to \$840m, making it the first pharma takeover of 2026. Through this transaction, Amgen will gain access to Dark Blue's pipeline of oncology assets – including DBT 3757, an investigational myeloid/lymphoid leukaemia translocation 1 and 3 (MLLT1/3)-targeted protein degrader. Currently in investigational new drug (IND)-enabling studies, DBT 3757 is being

developed for the treatment of acute myeloid leukaemia (AML), with preclinical work having already highlighted its anticancer potential.

Pharmaceutical Technologies 7.1.2026

Drug Approvals

Saphnelo approved in the EU for subcutaneous self-administration

AstraZeneca's *Saphnelo* (anifrolumab) has been approved in the European Union (EU) for subcutaneous self-administration as a pre-filled pen for adult patients with systemic lupus erythematosus (SLE) on top of standard therapy. The approval by the European Commission follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) and was based on the positive results from the Phase III TULIP-SC trial. In the trial, subcutaneous (SC) administration of *Saphnelo* led to a statistically significant and clinically meaningful reduction in disease activity compared to placebo in participants with moderate to severe, active, autoantibody-positive SLE while receiving standard therapy.

Pharmaceutical Manufacturer 16.12.2025

GSK obtains FDA approval for Exdensur in severe asthma

GSK has secured approval from the US Food and Drug Administration (FDA) for its severe asthma add-on maintenance therapy, Exdensur (depemokimab). This means that the long-acting interleukin-5 (IL-5)-targeting monoclonal antibody (mAb) is now indicated for use in patients aged 12 years or older with severe asthma characterised by an eosinophilic phenotype. The FDA's decision was based on the results of the Phase III SWIFT-1 (NCT04719832) and SWIFT-2 (NCT4718103) trials, which saw the therapy slash the prevalence of annualised asthma exacerbations by up to 58% over a 52-week treatment period.

Pharmaceutical Technologies 16.12.2025

Takeda and Protagonist seek FDA approval for rusfertide to treat PV

Takeda and Protagonist Therapeutics have jointly submitted a new drug application (NDA) seeking approval from the US Food and Drug Administration (FDA) for rusfertide to treat adults with polycythemia vera (PV). The first-in-class, subcutaneously administered hepcidin mimetic peptide, rusfertide is intended to regulate iron homeostasis and red blood cell production to help manage hematocrit levels in PV patients. The NDA follows positive results from the 32-week primary analysis and 52-week evaluation of the Phase III global placebo-controlled, randomised VERIFY trial

Pharmaceutical Technologies 6.1.2026

MHRA approves Nucala for eosinophilic COPD in adults on triple therapy

The MHRA has authorised GSK's Nucala (mepolizumab) in the UK as an add-on maintenance treatment for adults with uncontrolled COPD of an eosinophilic phenotype who are already receiving triple therapy with an inhaled corticosteroid, a long acting beta2-agonist and a long-acting muscarinic antagonist. The decision follows results from two placebo-controlled phase 3 studies, MATINEE and METREX, which demonstrated that mepolizumab significantly reduced the annualised rate of moderate or severe exacerbations and extended the time to first exacerbation once treatment had begun. The safety profile was consistent with what is already known for the medicine.

Pharma Times 6.1.2026

Tramipitant Becomes First Treatment Approved for Vomiting Due to Motion Sickness in 4 Decades

The FDA has approved tramipitant (Nereus; Vanda Pharmaceuticals) for the prevention of vomiting induced by motion, marking the first novel pharmacologic treatment for motion sickness in over 40 years. The approval, announced in a news release from Vanda Pharmaceuticals, represents a major advancement in the management of motion sickness. Results from 2 pivotal phase 3 clinical trials and an additional supporting study supported tramipitant's approval. Each of the pivotal trials (Motion Syros, NCT04327661; Motion Serifos, NCT05903924) was real-world provocation in nature and was conducted on boats

Pharmacy Times 2.1.2026

Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination

Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency for an extension of indication for teclistamab in combination with subcutaneous daratumumab for adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The company said the two immunotherapies act in a complementary way by targeting BCMA and CD38 to activate the immune system earlier in the treatment pathway.

Pharma Times 6.1.2026

China releases 2025 NRDL and first commercial insurance drug list

In early December, the 2025 updates of China's National Reimbursement Drug List (NRDL) were finalised with a total of 114 drugs, including Western drugs and traditional Chinese medicines, being newly introduced. Among the newly listed products, 50 are Class 1 innovative drugs, meaning that they have not been marketed anywhere in the world before receiving marketing authorisation in China. Apart from the NRDL annual update, the most significant change is the introduction of the country's first Commercial Insurance Innovative Drug List, which includes a total of 19 high-cost innovative drugs targeting diseases across cancer, Alzheimer's disease, and rare genetic disorders. The 2025 NRDL and the Commercial Insurance Innovative Drug List will take effect from 1 January 2026.

Pharmaceutical Technologies 2.1.2026

ASSOCIATION ACTIVITIES

Representations:

BDMAI made the following representations during the month;

GO MS NO. 27:

State Government of Telangana recently issued a notification allowing land conversion in the industrial areas within ORR. Based on the requests from several industries, BDMAI made a representation to the State Government requesting for keeping the above notification in abeyance till alternative location is identified with all facilities required or the bulk drug industries is identified outside the ORR. Please click [HERE](#) for the detailed representation.

We are happy to share that BDMAI received a response from DGFT, duly clarifying the issues raised in the above representation. Members may see:

[Representation](#)
[Response](#)

Suggestions/Inputs to CPCB for Common EPR Portal

BDMAI made some suggestions to Central Pollution Control Board on the proposed Common EPR Portal, copy of which is available [HERE](#)

Delays in obtaining NOCs for re-imports:

BDMAI received requests from some of the members that there are delays in obtaining NOCs for reimports from Customs, resulting in huge demurrages. BDMAI made a representations to the CBIC requesting for uniform SOPs across all the ports. Please click [HERE](#) for a detailed representation.

Circulars:

BDMAI sent the following circulars to the members about various events / updates:

Sl. No.	Subject	Issued on
1	Awareness Programme – Financial Schemes of SIDBI, MSME schemes for Pharma Industry & (NAPS) – 16th December 2025	<u>10.12.2025</u>
2	Lalitpur Pharma Park in UP - Interaction with Senior Government officials on 6.1.2026	<u>29.12.2025</u>

ASSOCIATION ACTIVITIES

Events:

Awareness Programme:

BDMAI organized an awareness programme on financial schemes available from SIDBI, MSME and also about National



Apprenticeship scheme, for the benefit of members, particularly MSMEs. The programme was well attended.



Interactive Meeting with UPSIDA:

A Pharma Park is being developed by the State Government of Uttar Pradesh at Lalitpur in about 350 acres, where some land is earmarked for the development of bulk drugs. A delegation of senior officers from UP State Industrial Development Authority visited

Hyderabad on 6th January 2026. BDMAI organized an interactive meeting with the delegation.



Aragen Life Sciences becomes a signatory to the UN Women's Empowerment Principles

We are proud to announce that Aragen Life Sciences has become a signatory to the UN Women's Empowerment Principles (WEPs) — a global initiative by UN Women and the UN Global Compact to advance gender equality and empower women in the workplace, marketplace, and community.

By joining WEPs, we reaffirm our commitment to:

- Building an inclusive workplace culture
- Promoting gender equality across all levels
- Increasing women's representation in our workforce to 25% by 2026

This milestone aligns with our broader sustainability and governance framework guided by the UNGC's Ten Principles. Diversity and inclusion are not just values for us, they are drivers of innovation and growth.

As part of the WEPs network, we look forward to collaborating with global peers, sharing best practices, and creating meaningful impact within Aragen and beyond. Together, we can empower women and create a more equitable future.



Powering Low-Carbon Pharma: Decarbonising and Digitalising Process Heat for Sustainable Manufacturing



Mr. Asad Hussain
Business Head - Process Heat Solutions
Thermax Limited

In the rapidly expanding landscape of pharmaceutical manufacturing in India, efficient and compliant utility systems are no longer just operational enablers, they are strategic differentiators. Process heat, delivered primarily through industrial boilers and heaters, is essential across various processes in the Pharma industry. However, as environmental regulations tighten and global buyers prioritise low-carbon supply chains, the industry must rethink how heat is generated, monitored, and optimised to both meet compliance and drive sustainability.

Growth, Regulation, and Sustainability Imperatives

India's pharmaceutical industry continues to be a cornerstone of global healthcare supply chains, contributing significantly to APIs, generics, and formulations. Domestically, this growth is supported by initiatives like Atmanirbhar Bharat, which aim to scale production while enhancing competitiveness. However, this expansion comes with heightened environmental responsibility, particularly in air emissions from combustion processes.

In August 2021, the Ministry of Environment, Forest and Climate Change (MoEFCC) issued dedicated air emission standards for pharmaceutical industries, covering boilers and incinerators among other sources. The notification mandates compliance with pollutant limits and requires Continuous Emission Monitoring Systems (CEMS) on larger boilers to ensure real-time accountability, in line with guidelines issued by the Central Pollution Control Board (CPCB). This shift elevates emissions monitoring from periodic checks to continuous, automated compliance reporting.

Industrial boilers, including those in pharma manufacturing, are significant contributors to India's greenhouse gas emissions. According to reporting by the Economic Times, industrial boilers account for an estimated 7% of the nation's total CO₂ emissions due to fossil fuel use and outdated combustion systems.

Globally, major healthcare procurement systems are increasingly requiring lower carbon footprints in their supplier bases, making decarbonisation a market access priority as well as a compliance necessity.

Concurrently, India has committed to achieving net zero greenhouse gas emissions by 2070, along with interim targets such as reducing CO₂ emissions intensity and expanding renewable capacity. These strategies are part of a broader energy transition roadmap discussed by British Safety Council India, which highlights both progress and the need for enhanced finance and technological deployment to meet long-term climate goals.

Why Process Heat Decarbonisation Matters in Pharma

Boilers and heaters are among the most energy-intensive assets in any pharmaceutical facility. Traditional fossil fuels such as coal, oil, and natural gas not only emit CO₂ but also particulate matter and other harmful pollutants that must be rigorously controlled under environmental norms. At the same time, thermal loads in pharma often demand reliability and precision, which makes simple fuel substitution challenging without advanced technologies.

Biomass as a Carbon-Neutral Fuel

Biomass, including agro-residues and sustainably sourced organic fuels, is widely recognised as carbon-neutral because the CO₂ emitted during combustion is offset by the CO₂ absorbed during growth. This makes biomass an attractive option for steam and heat generation in pharma utilities. However, burning biomass poses technical challenges:

- Variability in fuel quality
- Moisture content affecting combustion stability
- Ash and clinker formation requiring robust handling systems

These complexities demand specialised combustion technologies such as reciprocating grates and staged air systems that ensure efficient and complete combustion with low emissions.

Advanced Combustion Solutions for Biomass

Among available technologies, reciprocating grate combustion has emerged as one of the most advanced, automated, and robust solutions, particularly for challenging biomass fuels. Its design strongly supports the time, temperature, and turbulence requirement essential for complete combustion. The reciprocating movement of the grate enables controlled agitation and gradual progression of fuel, which supports uniform exposure to heat and helps maintain combustion

stability despite variations in moisture or size. The multiple-trolley grate configuration divides the furnace bed into distinct combustion zones, each with independently controlled residence time and combustion air supply, governed by a hydraulic power pack. This physical separation, along with individualised air control, ensures optimum combustion conditions across all stages while helping maintain lower auxiliary power consumption for air supply. Additionally, the availability of multiple grate bar geometries ensures width-wise distribution of air, helping to avoid localised tongue-type flame formation and promoting uniform firing across the grate. Together, these attributes enhance fuel burnout, reduce clinker formation and fouling, improve efficiency, and support higher uptime, making reciprocating grate technology highly suitable for pharmaceutical utilities that require reliability with compliance assurance.

Renewable Electricity and Electric Boilers

Another pathway to near-zero emissions is the electrification of process heat where feasible. Low-voltage (LV) electric boilers powered by renewable electricity offer a compelling alternative, especially for moderate thermal loads. With solar and wind capacity rapidly expanding in India's energy mix, electric boilers present a route to zero global emissions, provided the electricity source is decarbonised.

Electric boilers bring additional advantages:

- Clean combustion with zero onsite emissions
- Fast response and precise control
- Simplified maintenance due to fewer mechanical parts

In applications with compatible temperature ranges, they can significantly reduce a plant's direct carbon footprint.

Digitalisation: The Key to Compliant and Efficient Heat Operations

Digitalisation transforms decarbonisation efforts from isolated upgrades into systemic enablers of performance and compliance. Industrial Internet of Things (IIoT) technologies allow real-time monitoring and control of boilers and heaters across facilities.

Key benefits of IIoT in process heat include:

- Remote and continuous performance insights
- Automated alerting for emissions exceedances
- Predictive maintenance to prevent unplanned downtime
- Data-driven optimisation for fuel and energy efficiency

When integrated with plant supervisory controls, these systems can automatically adjust combustion and load following based on operating conditions, leading to lower emissions and improved safety.

Artificial Intelligence for Smart Combustion Control

Taking digitalisation further, AI-enabled control systems analyse sensor data to optimise boiler combustion in real time. By learning from historical and operational data:

- Fuel feed and air supply can be precisely balanced
- Transient conditions can be predicted and mitigated
- Emission profiles can be minimised dynamically

AI doesn't just automate control, it continuously improves it, making boilers safer, cleaner, and more efficient over time.

Conclusion: Future-Ready Heat for Pharma's Sustainability Roadmap

As India's pharmaceutical industry scales to meet global demand, it must also prepare for a future where low-carbon performance and digital compliance are prerequisites for competitiveness. Decarbonised heat solutions, from biomass combustion technologies and electric boilers to digital and AI-driven optimisation, provide a roadmap not only for regulatory compliance but also for strategic sustainability leadership.

Adopting these technologies will empower pharma manufacturers to:

- Comply reliably with evolving emissions standards
- Reduce carbon footprints and enhance ESG performance
- Mitigate operational risks through real-time insights
- Deliver products aligned with global buyers' low-carbon expectations

In this new industrial era, smart, low-carbon process heat isn't just part of utilities, it's part of value creation for the pharmaceutical enterprise.

IMPORTS OF APIs & Intermediates

APRIL - OCTOBER

Value in US \$ mn

HS Code	Description	2024-25	2025-26
17023010	Glucose liquid	0.0414	0.0916
17023020	Glucose solid	0.5168	0.4865
17023031	Dextrose,solid	0.5044	0.3985
17023039	Dextrose other than solid	0.6466	0.8724
17024039	Dextrose other than solid	0.1129	0.1324
29051410	Ethambutol, ethambutol hcl	2.6040	2.1289
29051420	Salbutamol sulphate	0.2049	0.2788
29054300	Mannitol	34.8691	37.7509
29054400	D-glucitol (sorbitol)	7.3061	7.1530
29071930	Thymol	0.0611	0.0736
29072200	Hydroquinone	22.6816	22.6012
29095010	Guaiacol	0.9425	2.0426
29124930	Thiacetazone	0.0118	0.0000
29124940	3,4,5-trimethoxy-benzaldehyde	0.2708	0.2901
29154010	Monochloroacetic acid their salts	1.8672	1.1542
29163120	Benzyl Benzoate	0.3544	0.6971
29163150	Benzocaine (ethylpara-amino benz	0.0186	0.0830
29163400	Phenyl acetic acid	4.2645	1.4963
29171940	Ferrous fumerate	0.0279	0.0473
29171970	Ethoxy methylene malonate, dieth	13.3122	9.8430
29181120	Calcium lactate	0.2797	0.1842
29181320	Metroprolol tartrate	0.5463	1.3333
29181510	Potassium citrate	1.2572	0.6280
29181520	Sodium citrate	1.5457	2.8801
29181550	Ferric ammonium citrate	0.0050	0.0139
29181610	Calcium gluconate	5.9624	5.1825
29182110	Salicylic acid	19.2018	14.0859
29182120	Sodium salicylate	0.0391	0.1108
29182200	O-acetylsalicylic acid its salts and es	0.4252	0.3714
29182310	Methyl salicylate	0.7467	0.5743
29182320	Amino salicylate	0.0000	0.0334
29183030	Nalidixic acid	0.5599	0.3199
29199010	Glycerophosphoric acid	0.0023	0.0408
29214600	amfetamine INN and its related api	0.3008	0.2130
29215110	o phenylanediamine	11.4633	7.9445
29215120	M-phenylenediamine (m-di aminob	2.6354	2.4099
29215130	P-phenylenediamine	3.2560	2.7216
29223100	Amfepra none(inn), methdone & m	0.0000	0.0007
29224100	Lysine and its esters salts thereof	80.4698	75.4811
29224210	Glutamic acid	0.5164	0.5385
29224220	Monosodium glutamate (aginamot	41.0908	41.3914
29224400	Tilidine (INN) and its salts	0.0000	0.0004
29224910	Amino acetic acid (glycine)	18.0770	12.1153
29224920	N-methyl taurine	0.7631	2.5262
29225011	Para-amino-salicylic acid	0.1196	0.0122
29225013	Procaine hydrochloride	0.0000	0.0143

29225015	L-tyrosine(p-hydroxyphenylamine)	1.5478	2.1803
29225021	Frusemide	0.3622	0.2473
29231000	Choline and its salts	1.9391	1.5972
29241100	Meprobamate (inn)	1.8124	0.8097
29242500	Alachlor	0.0000	0.0035
29242910	Acetanilide	9.7278	8.5087
29242960	Pyrazinamide(pyrazine carboxamid	0.9507	0.6584
29242970	Pretilachlor	1.6941	2.2327
29242980	Paracetamol	3.8389	8.7190
29262000	1-Cyanoguanidine (dicyandiamide)	51.5590	38.3104
29263000	Fenproporex (inn) & its salts	0.0000	0.9453
29264000	Alpha-phenylacetoacetonitrile	0.0685	0.2014
29280010	Isoniazid	1.7154	2.6837
29309014	Industrial chemical	0.0000	8.5303
29309040	L-cystine (alpha-amino beta-thiopr	11.9071	0.0000
29322010	Coumarin,mthylcoumrn & ehylcou	0.7546	0.5735
29329300	3 -Carboxy(Para sulpho- phenyl)-5-	2.1775	0.9523
29329600	Carbofuran	0.0000	2.5363
29331100	Phenazone (antipyrin) and its deriv	0.8870	1.0003
29331910	3-carboxy (para sulpho-phenyl)-5-	0.1414	0.5882
29331920	1 (2,5- dichloro-4-sulpho phenyl)-3	0.0731	0.3300
29331930	3-methyl-1(4-sulpho-O-toluyl-5-pyr	0.0023	0.0018
29331940	Phenylmethylpyrazolone	0.6604	0.4941
29331950	1-phenyl-5-pyrazolone-3-carboxylic	0.0004	0.2856
29331960	1-(m-sulphophenyl)-3-pyrazolone	0.2751	0.4332
29331970	Analgin	2.6810	1.4710
29331980	Oxyphenbutazone	0.0134	0.1508
29332910	Tinidazole	0.0459	0.2509
29332920	Metronidazole metronidazole ben	7.9191	6.6179
29332930	Mebendazole	0.1177	0.0506
29332940	Dimetridazole	0.1169	0.0000
29334190	Other Containing structure of quin	0.0000	0.0288
29335200	Malonylurea (barbituric acid) & its	3.2378	4.0461
29335300	Allobarbital and othr barbital comp	0.1900	0.0375
29335400	Other derivatives of malonylurea (b	0.0072	0.8187
29335500	Loprazolam, mecloqualone, metha	0.0007	0.0004
29335910	Aminophylline(cordophylin)	0.3722	0.1421
29335920	Trimethoprim	0.2280	0.2666
29335940	1-Amino-4-Methyl piperazine	0.0120	0.0185
29335950	Bispiribac Sodium(Herbicide)	0.0002	0.0105
29339100	Alpra zolam, camazepam & other c	1.6840	1.2772
29339200	Azinphos-methyl (ISO)	0.0001	0.0004
29349100	Aminorex, brotizolam and other lik	0.0226	0.0004
29349200	Fentanyl	0.5285	0.3278
29349910	Chloro Thiophene-2-Carboxylic Aci	0.3688	0.6243
29349930	Pramoxine	0.0020	0.0028
29349940	Other Hetrocyclic compounds	0.0000	0.0010
29349990	Other Hetrocyclic compounds	452.8899	444.8336
29351000	N-Methylperfluorooctane sulphona	0.0224	0.0001
29355090	Other Perfluro Octane Suphonomid	0.0566	0.9605

29359011	Sulphamethoxazole	0.0260	0.0400
29359013	Sulphadiazine	0.4494	0.5602
29359014	Sulphadimidine	1.0514	1.2596
29359023	Sulphamoxole	0.0003	0.0000
29359024	Sulfamide	0.4845	0.7356
29359040	Pyrazosuluron ethyl(Pesticide)	0.0000	0.4054
29362100	Vitamins a and their derivatives	9.4087	12.3521
29362210	Vitamin b1i(thiamine, aneurine) & i	10.6036	17.4261
29362290	Other vitamin b1i and its drivatives	2.1488	1.8018
29362310	Vitamin b2 (riboflavin, lactoplatin)	8.7204	6.4268
29362390	Other vitamin b2 and its derivative	3.9008	1.9905
29362400	D-or dl-pantothenic acid (vitamin b	6.3549	8.6547
29362500	Vitamin b6 & its drvts	9.7732	8.6335
29362610	Vitamin b12 (cynocobalamin)	18.2497	21.4951
29362690	Other vitamin b12 and its derivativ	1.2386	2.6105
29362700	Vitamin c (ascorbic acid) & its drvtv	14.3991	21.8495
29362800	Vitamin e and its derivatives	31.3998	39.1086
29362910	Folic acid (vitamin b9)	1.8052	4.5006
29362920	Nctnc acid & nctnmd(niacinamide/	1.1658	0.8267
29362930	Vitamin k (menaphthonum b.p.)	1.7373	1.4364
29362940	Vitamin d	9.1906	11.5538
29362950	Vitamin h (bi0lin)	1.0719	1.1746
29362990	Other vitamins and thr drvtvs	13.9771	8.9373
29369000	Other, incl. natural concentrts	0.8242	1.8590
29371100	Somatotropin, its drvtvs& strctl ana	0.0077	0.0027
29371200	Insulin and its salts	19.6337	34.7449
29371900	Other polypeptide hormones thr dt	26.8989	44.5366
29372100	Cortisone,hydrocortisone,predniso	28.0044	23.6564
29372200	Halgntd drvtvs of corti costeroidal	18.8000	17.7173
29372300	Oestrogens and progestogens	41.3214	37.4028
29372900	Othr steroidal hormons thr drvtvs a	72.5741	66.9192
29373100	Epinethrine	0.0000	0.0010
29375000	Prostaglandins, tiromboxames& leu	4.1655	3.0124
29379011	Epinethrine	0.0012	0.0030
29379019	Other Catecholamine hormones, th	3.4474	3.0020
29379020	Amino acid Derivatives	8.0786	4.9799
29379090	Other Amino acid Derivatives	39.3319	40.6998
29381000	Rutoside (rutin) and its derivatives	3.9101	3.0960
29389010	Digoxin	0.0267	0.1122
29389020	Digitalis glycosides	0.0856	0.0244
29389090	Other glycosides ntrl/rprdcn by syn	48.4075	41.2279
29391100	Concentrates of poppy straw cmpn	17.7371	2.1337
29392010	Quinine alkaloids	0.4821	0.6816
29392020	Quinine hydrochloride	0.0039	0.2942
29392030	Quinine sulphate	0.3452	0.2117
29393000	Caffeine and its salts	14.7783	22.9146
29394100	Ephedrine & its salts	0.0086	0.0949
29394300	Cathine(INN) & its salts	0.0004	0.0021
29394400	Norephedrine and its salts	0.0008	0.0149
29394500	Levo Methaphatamine	0.0010	0.0008

29394900	Other ephedrines and their salts	0.3904	0.5257
29395900	Other theophylline and aminophylline	3.3288	3.2587
29396190	Other ergometrine salts	0.0958	0.1253
29396210	Ergotamine tartarate	0.7372	0.0000
29396290	Other ergotamine salts	0.0355	0.0000
29396900	Other alkaloids of rye ergot & drvtv	2.7811	1.6550
29397200	Cocaine, ecgonine, levometamfeta	0.2551	0.0006
29397900	Other of Vegetable origin	3.5414	7.2972
29398000	Non Vegetable Alkaloids	6.8387	2.8153
29411010	Penicillins and its salts	154.4526	84.3080
29411020	Ampicilline & its salts	0.3078	0.4628
29411030	Amoxycilline & its salts	30.0152	24.3630
29411040	Cloxacilline & its salts	0.4017	0.6048
29411050	6 - apa	292.7795	228.1576
29411090	Other penicillins & their drvtvs wth a	54.8368	56.3162
29412010	Streptomycins	3.9717	3.5384
29412090	Other streptomycine & drvtvs, salts	1.7524	1.3169
29413010	Doxycycline & its salts	13.3174	19.0945
29413020	Tetracycline/oxytetra - cycline & hr	6.8522	7.8274
29413090	Other tetracyclines & their drvtvs slts	15.1596	14.6052
29414000	Chloramphenicol & its drvtvs slts th	1.7821	0.2674
29415000	Erthromycin & its drvtvs slts thereo	110.6158	125.6669
29419011	Rifampicin	24.1267	40.3927
29419013	Rifa S or Rifa S Sodium (Rifaint)	9.9390	26.1434
29419014	1-Amino-4-Methyl piperazine (Rifai)	0.0759	0.0000
29419019	Other rifampicin and its salts	37.4167	39.8635
29419020	Cephalexin & its salts	22.3802	18.7273
29419030	Ciprofloxacin & its salts	6.9992	3.4878
29419040	Gentamycin & its salts	5.2620	5.0528
29419050	Neomycin	1.9508	2.1031
29419060	Norfloxacin & its salts	8.5677	4.1899
29419090	Other antibiotics	508.0864	515.6375
29420011	Cefadroxil	1.4004	0.9453
29420012	Ibuprofane	4.3415	5.4197
29420013	Nifedipine	0.0098	0.0928
29420014	Ranitidine	0.1138	0.1889
29420015	Danes salt of D(-) phenyl glycine	13.6851	12.3928
29420016	Timolo maleate, terbutoline sulphate	17.6415	13.7241
29420021	Timolol maleate	0.3091	0.1364
29420022	Terbutoline sulphate	0.0000	0.0228
29420023	D(-) phenyl glycine chloride HCL (DP)	0.0000	0.0367
29420025	Amitriptyline hcl	0.0290	0.0000
29420026	Cysteanune hcl	1.8523	2.5196
29420027	Atenolol, propranolol	1.0175	0.8661
29420032	Cimetidine	0.5492	0.3131
29420033	Oxyclozanide	0.0087	0.0000
29420034	Famotidine	0.2030	0.3189
29420090	Other diloxanide furoate, cimetidine	214.4997	213.5618
96020030	Gelatin capsules,empty	3.3577	2.9736
		2926.5988	2817.9537

EXPORTS OF APIs & INTERMEDIATES			
April-October			
		Value in \$ Million	
HS Code	Description	2024-25	2025-26
17023010	Glucose liquid	35.8731	35.6728
17023020	Glucose solid	7.8046	4.5025
17023031	Dextrose,solid	10.9307	10.8531
17023039	Dextrose other than solid	0.2220	0.2171
17024039	Dextrose other than solid	0.0795	0.0497
29051410	Ethambutol, ethambutol hcl	5.0543	3.1321
29051420	Salbutamol sulphate	8.2236	7.2821
29054300	Mannitol	3.7601	4.6666
29054400	D-glucitol (sorbitol)	42.0918	43.6166
29071930	Thymol	5.7810	4.4829
29072200	Hydroquinone	6.7564	7.9602
29095010	Guaiacol	1.1810	1.5988
29124940	3,4,5-trimethoxy-benzaldehyde	1.5440	1.4767
29154010	Monochloroacetic acid their salts and	9.5385	7.7363
29163120	Benzyl Benzoate	3.7465	2.3207
29163150	Benzocaine (ethylpara-amino benzoate)	1.2844	2.2852
29163400	Phenyl acetic acid	0.7812	0.7207
29171940	Ferrous fumerate	5.6843	4.8851
29171970	Ethoxy methylene malonate, diethyl ma	0.0050	0.1640
29181120	Calcium lactate	0.1671	0.0986
29181320	Metroprolol tartrate	6.2218	6.4216
29181510	Potassium citrate	2.0243	1.6590
29181520	Sodium citrate	6.9870	7.2641
29181550	Ferric ammonium citrate	0.4535	0.7924
29181610	Calcium gluconate	5.1128	3.3973
29181620	Ferrous gluconate	0.7697	0.4346
29182110	Salicylic acid	1.8823	2.3875
29182120	Sodium salicylate	1.8287	1.5498
29182200	0-acetylsalicylic acid its salts and estrs	0.9288	1.0072
29182310	Methyl salicylate	5.0445	5.3619
29182320	Amino salicylate	0.3605	0.4096
29183030	Nalidixic acid	1.1977	0.6222
29199010	Glycerophosphoric acid	0.0184	0.0417
29199030	Iron glycerophosphate	0.0407	0.0132
29214250	Herbicide	0.0000	13.9449
29214600	amfetamine INN and its related apis	19.6663	43.4813
29215110	o phenylanediamine	0.6095	0.7120
29215120	M-phenylenediamine (m-di aminobenze	6.0380	17.3857
29215130	P-phenylenediamine	7.2821	4.9662
29215170	Para amini acetanalide	0.1701	0.3318
29223100	Amfepra none(inn), methdone & morm	0.3281	0.6292
29224100	Lysine and its esters salts thereof	1.5046	2.4903
29224210	Glutamic acid	0.1507	0.1790
29224220	Monosodium glutamate (aginamoto)	0.4473	0.3808
29224400	Tilidine (INN) and its salts	0.2332	0.0375
29224910	Amino acetic acid (glycine)	15.8296	10.5138

29224920	N-methyl taurine	0.0193	0.0340
29225011	Para-amino-salicylic acid	0.0014	0.0075
29225013	Procaine hydrochloride	0.0519	0.0930
29225015	L-tyrosine(p-hydroxyphenylamine)	0.0091	0.0043
29225021	Furosemide	12.5202	11.5611
29225024	D0mperid0ne	5.3043	4.4392
29231000	Choline and its salts	7.4587	5.3045
29241100	Meprobamate (inn)	2.6140	0.3548
29242910	Acetanilide	0.2139	0.0831
29242960	Pyrazinamide(pyrazine carboxamide)	4.0136	2.1578
29242970	Pretilachlor	0.0372	10.9123
29242980	Paracetamol	45.5702	52.8987
29262000	1-Cyanoguanidine (dicyandiamide)	0.0017	0.1001
29263000	Fenproporex (inn) & its salts	0.0372	0.0002
29264000	Alpha-phenylacetoacetonitrile	0.0000	0.0134
29280010	Isoniazid	0.7214	0.6643
29309014	Industrial chemical	0.0000	3.4556
29309040	L-cystine (alpha-amino beta-thiopropion	2.1095	0.0000
29322010	Coumarin,mthylcoumrn & ehylcoumrn-l	6.5634	7.1863
29329300	3 -Carboxy(Para sulpho- phenyl)-5-Pyraz	0.1847	0.0000
29329600	Carbofuran	0.0069	0.3415
29331100	Phenazone (antipyrin) and its derivative	6.4721	6.4123
29331910	3-carboxy (para sulpho-phenyl)-5- pyraz	1.1839	1.4719
29331920	1 (2,5- dichloro-4-sulpho phenyl)-3-met	0.5602	6.5234
29331930	3-methyl-1(4-sulpho-O-tolyl-5-pyrazol	0.7036	0.0843
29331940	Phenylmethylpyrazolone	0.0221	0.0249
29331950	1-phenyl-5-pyrazolone-3-carboxylic acid	0.0191	0.0024
29331960	1-(m-sulphophenyl)-3-pyrazolone	0.0000	0.0594
29331970	Analgin	0.0732	0.0000
29332910	Tinidazole	2.2711	2.6681
29332920	Metronidazole metronidazole benzoate	9.6513	11.4709
29332930	Mebendazole	3.5177	4.9940
29332940	Dimetridazole	5.1553	2.6382
29334100	Levorphanol (inn) and its salts	1.3502	0.0000
29334110	Levorphanol (inn) and its salts	0.0000	0.6570
29334190	Other Containing structure of quinoline	0.0000	2.7943
29335200	Malonylurea (barbituric acid) & its sals	0.3170	0.7901
29335300	Allobarbital and othr barbital compnds a	3.0285	1.7349
29335400	Other derivatives of malonylurea (barbi	1.0286	1.1092
29335910	Aminophylline(cordophylin)	0.4727	0.4175
29335920	Trimethoprim	8.3621	8.5615
29335930	Diethyl carbanazine citrate	0.6588	0.1910
29335940	1-Amino-4-Methyl piperazine	1.9406	4.9930
29335950	Bispirbac Sodium(Herbicide)	0.6906	6.4320
29339100	Alprazolam, camazepam & other cmpn	13.8080	13.2931
29339200	Azinphos-methyl (ISO)	0.1054	0.2035
29349100	Aminorex, brotizolam and other like cm	4.4744	9.2340
29349200	Fentanyl	0.0615	0.5432
29349910	Chloro Thiophene-2-Carboxylic Acid	0.0439	0.0376
29349920	Morpholine	10.1140	9.3566

29349930	Pramoxine	0.0417	6.4305
29349940	Other Hetrocyclic compounds	0.0000	23.9897
29349990	Other Hetrocyclic compounds	382.1245	454.9721
29351000	N-Methylperfluorooctane sulphonamid	0.0453	0.2686
29352000	N-Ethylperfluorooctane sulphonamide	0.0000	0.0408
29355090	Other Perfluro Octane Suphonomides	1.1861	1.0992
29359011	Sulphamethoxazole	22.8334	18.9830
29359012	Sulphafurazole	0.0059	0.0017
29359013	Sulphadiazine	3.6655	4.4042
29359014	Sulphadimidine	0.0539	0.0182
29359015	Sulphacetamide	0.0062	0.0233
29359022	Sulphamethiazole	0.0000	3.0074
29359024	Sulfamide	0.0000	0.0003
29359040	Pyrazosuluron ethyl(Pesticide)	0.0000	9.8184
29362100	Vitamins a and their derivatives	15.2636	13.6273
29362210	Vitamin b1i(thiamine, aneurine) & its sa	7.2541	7.1802
29362290	Other vitamin b1i and its drivatives	14.2932	9.1962
29362310	Vitamin b2 (riboflavin, lactoplavin) and i	7.2287	8.3641
29362390	Other vitamin b2 and its derivatives	0.1400	0.0936
29362400	D-or dl-pantothenic acid (vitamin b3 or	0.5219	0.2534
29362500	Vitamin b6 & its drvts	0.1430	0.5912
29362610	Vitamin b12 (cynocobalamin)	0.4546	1.0380
29362690	Other vitamin b12 and its derivatives	2.7610	7.1139
29362700	Vitamin c (ascorbic acid) & its drvtvs	6.9357	8.2302
29362800	Vitamin e and its derivatives	12.8470	16.6717
29362910	Folic acid (vitamin b9)	3.6805	4.1757
29362920	Nctnc acid & nctnmd(niacinamide/niaci	60.9374	52.5568
29362930	Vitamin k (menaphthonum b.p.)	4.6805	6.1089
29362940	Vitamin d	14.8190	19.6669
29362950	Vitamin h (bi0lin)	0.5611	0.3568
29362990	Other vitamins and thr drvtvs	12.5168	12.5537
29369000	Other, incl. natural concentrts	27.7109	37.6747
29371100	Somatotropin, its drvtvs& strctl analogv	0.2097	0.0668
29371200	Insulin and its salts	27.7098	26.4902
29371900	Other polypeptide hormones thr dtvtvs	21.6847	27.2067
29372100	Cortisone,hydrocortisone,prednisone (d	8.2056	8.5264
29372200	Halgntd drvtvs of corti costeroidal	23.1504	21.7323
29372300	Oestrogens and progestogens	15.9458	17.2327
29372900	Othr steroidal hormons thr drvtvs and s	74.7060	74.7911
29373100	Epinethrine	0.0000	0.0000
29375000	Prostaglandins, tiromboxames& leukotr	1.4440	1.0250
29379011	Epinethrine	0.0069	0.0000
29379019	Other Catecholamine hormones, their d	0.8160	0.4246
29379020	Amino acide Derivatives	14.8427	8.9236
29379090	Other Amino acide Derivatives	18.9513	14.3348
29381000	Rutoside (rutin) and its derivatives	0.0018	0.0013
29389010	Digoxin	1.3484	1.0193
29389090	Other glycosides ntrl/rprdcd by synthsis	27.9166	51.9083
29391100	Concentrates of poppy straw cmpnds of	0.9399	0.1321
29392010	Quinine alkaloids	0.0000	0.0000

29392020	Quinine hydrochloride	1.4576	2.8603
29392030	Quinine sulphate	0.7832	0.3429
29392040	Chl0r0quine ph0sphate	1.1003	1.1070
29393000	Caffeine and its salts	38.2229	45.9977
29394100	Ephedrine & its salts	1.3888	1.5271
29394400	Norephedrine and its salts	1.3964	2.2652
29394500	Levo Methaphatamine	0.0755	0.0001
29394900	Other ephedrines and thr salts	1.6515	1.1955
29395900	Other theophylline and aminophylline t	23.8787	30.4096
29396110	Ergometrine	0.0004	0.0000
29396190	Other ergometrine salts	0.0040	0.0000
29396210	Ergotamine tartarate	0.0036	0.0000
29396900	Other alkaloids of rye ergot & drvtvs	1.5573	1.1515
29397900	Other of Vegitable origin	80.1133	107.5914
29398000	Non Vegetable Alkaloids	10.6426	9.5360
29411010	Penicillins and its salts	0.0153	0.1381
29411020	Ampicilline & its salts	17.8406	15.3602
29411030	Amoxycilline & its salts	124.5045	100.1435
29411040	Cloxacilline & its salts	15.8408	14.2325
29411050	6 - apa	0.0000	0.0001
29411090	Other penicillins & thr drvtvs wth a pent	59.9959	50.6544
29412010	Streptomycins	0.0072	0.0323
29412090	Other streptomycine & drvtvs, salts	0.0213	0.2904
29413010	Doxycyclime & its salts	0.4275	0.5810
29413020	Tetracycline/oxytetra - cycline & hr salts	1.5189	0.7102
29413090	Other tetracyclines & thr drvtvs slts	0.2990	0.2269
29414000	Chloramphenicol & its drvtvs slts thereo	1.5958	1.4750
29415000	Erthromycin & its drvtvs slts thereof	68.0197	62.2294
29419011	Rifampicin	6.6022	9.1677
29419012	3 Formyl Rifa S V(Rifaint)	0.0000	0.0000
29419013	Rifa S or Rifa S Sodium (Rifaint)	0.2014	0.0000
29419014	1-Amino-4-Methyl piperazine (Rifaint)	0.0000	0.0000
29419019	Other rifampicin and its salts	5.9231	3.1018
29419020	Cephalexin & its salts	7.0849	4.2589
29419030	Ciprofloxacine & its salts	14.0312	15.1081
29419040	Gentamycin & its salts	0.0327	0.0120
29419050	Neomycin	0.0178	0.0696
29419060	Norfloxacin & its salts	1.1798	1.4265
29419070	Other antibiotics	0.0000	0.0024
29419090	Other antibiotics	370.0913	308.0322
29420011	Cefadroxil	12.5542	12.4742
29420012	Ibuprofane	48.8690	45.1812
29420013	Nifedipine	1.0820	2.0011
29420014	Ranitidine	6.8091	5.2206
29420015	Danes salt of D(-) phenyl glycine	0.1531	0.0000
29420016	Timolo maleate, terbutoline sulphate, i	0.0041	0.0221
29420021	Timolol maleate	3.3474	2.8445
29420022	Terbutoline sulphate	0.8518	0.8015
29420024	Imipramine hcl	0.4382	0.6128
29420025	Amityptyline hcl	4.0099	3.7689

29420026	Cysteanune hcl	0.0001	0.0000
29420027	Atenolol, propranolol	7.2472	7.8159
29420031	Diloxanide furoate	1.4659	2.1942
29420032	Cimetidine	0.0008	0.0351
29420033	Oxyclozanide	3.9929	6.0365
29420034	Famotidine	8.3968	9.1665
29420090	Other diloxanide furoate, cimetidine, fa	696.1182	700.1359
96020030	Gelatin capsules,empty	57.6078	53.3289
		2950.2300	3091.6490